Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

TRACON gets US$5mln and licensing deal from Janssen

Tuesday, October 4, 2016 7:01
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Tracon Pharmaceuticals Inc (NASDAQ:TCON) has signed rights for two oncology inhibitors being developed by Johnson & Johnson subsidiary Janssen (NYSE:JNJ).

A Phase 1/2 proof-of-concept (POC) clinical trial for one of the molecules, TRC253, in prostate cancer applications is exxpected in the first half of next year.

The other, TRC694 is currently in preclinical development, with an investigational new drug application expected to be filed in 2018.

As part of the deal, Janssen will invest US$5mlnin in Tracon, money that provide development funding for its current lead product carotuximab.

It has orphan drug status for soft tissue sarcoma and fast track status for kidney cancer. 

Story by ProactiveInvestors

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.